Shanghai-based oncotherapy-focused firm Hrain biotechnology Co., Ltd. announces on Monday that it raises RMB200 million (US$28 million) in a series B funding round led by venture capital firm Shenzhen Capital Group (SCG).
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?